C4X Discovery Holdings plc
("C4XD", "C4X Discovery" or the "Company")
Director/PDMR Share Purchases
9 April 2024 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, was informed on 8 April 2024 that Clive Dix, Executive Chairman of the Company, purchased 485,320 ordinary shares of 0.01 pence each ("Ordinary Shares") in the Company at a price of 10.3 pence per share.
Following this purchase of shares, Clive Dix has a beneficial interest in 2,071,809 Ordinary Shares, representing approximately 0.82 per cent. of the Company's issued share capital.
Further information on the purchases is contained in the disclosure tables below.
Contacts
| C4X Discovery Holdings | |
| Mo Noonan, Communications | +44 (0)787 6444977 |
| | |
| Panmure Gordon (UK) Limited (NOMAD and Broker) | |
| Freddy Crossley, Emma Earl (Corporate Finance) | +44 (0)20 7886 2500 |
| Rupert Dearden (Corporate Broking) | |
| | |
| C4X Discovery Media - Consilium Strategic Communications | |
| Mary-Jane Elliott, Chris Gardner | +44 (0)203 709 5700 |
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM:
| 1 | Details of the person discharging managerial responsibilities / person closely associated | |||||
| a) | Name | Clive Dix | ||||
| 2 | Reason for the notification | |||||
| a) | Position/status | Executive Chairman | ||||
| b)
| Initial notification /Amendment | Initial notification | ||||
| 3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
| a) | Name | C4X Discovery Holdings plc | ||||
| b) | LEI | 213800UHNL82E323O870 | ||||
| 4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| a)
| Description of the financial instrument, type of instrument Identification code | Ordinary shares of £0.01 each
GB00BQQ2RV18 | ||||
| b) | Nature of the transaction | Purchase of Shares | ||||
| c) | Price(s) and volume(s) |
| ||||
| d) | Aggregated information - Aggregated volume - Price |
n/a | ||||
| e) | Date of the transaction | 8 April 2024 | ||||
| f) | Place of the transaction | London Stock Exchange
| ||||
Notes to Editors:
About C4X Discovery
C4X Discovery (C4XD) is a pioneering Drug Discovery company, combining scientific expertise with cutting-edge technologies to efficiently deliver world‑leading medicines. We have a highly valuable and differentiated approach to Drug Discovery through our enhanced molecular design and patient stratification capabilities, generating small molecule drug candidates across multiple disease indications focused on immuno-inflammation. We are advancing our internal portfolio which ranges from early-stage target opportunities to late-stage Drug Discovery programmes and we have two commercially partnered programmes with Sanofi and AstraZeneca, and one clinical stage candidate which has been acquired by Indivior.
For more information visit us at www.c4xdiscovery.com or follow us on twitter @C4XDiscovery.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.